Charting the Biosimilar and Biobetter Development Pipeline
|出版日||ページ情報||英文 213 Pages
|バイオシミラー・バイオベター開発パイプラインのチャート Charting the Biosimilar and Biobetter Development Pipeline|
|出版日: 2013年07月01日||ページ情報: 英文 213 Pages||
If you need to understand the important biosimilar and biobetter drug developments worldwide then this report is critical.
The promise of biosimilars has been great but beyond the first wave of products progress has been slow. With a number of high-value biologics, particularly monoclonal antibodies such as Herceptin, Avastin, Remicade and Humira, losing patent expiry in the coming years the potential for biosimilars remains high. With greater clarity on regulatory approval and the demand of health payers for low cost medicines, the drive to develop a viable biosimilar market will continue to grow.
Who are the companies involved? What does their portfolio look like? What stage are they at? Which products offer the best potential in terms of competitor development? Critical questions needing robust answers. That is where Charting the Biosimilar and Biobetter Development Pipeline (2013) comes in.
The massively expanded second edition of this leading drug intelligence report provides a complete, practical and highly-detailed insight into the status of 868 biosimilar/biobetter drugs in development from over 300 companies worldwide. Widely considered to be the most comprehensive analysis of its type, Charting the Biosimilar and Biobetter Development Pipeline (2013) is delivered in two modules:
1. Biosimilar Datafile - New this edition!
Enjoy the practical benefits of a Microsoft Excel file containing data on biosimilar and biobetter drugs currently marketed or known to be in clinical development worldwide. Each drug can be seen in the context of data on their biologic reference products and content can readily be filtered on key indicators such as:
Using the tables provided you can effortlessly drill down into the content to identify biosimilars/biobetters in development by country, company, ATC classification, stage of development, and therapeutic area. Better still, the data can easily be exported to your own analytics or competitive intelligence system.
2. Biosimilar Development Analysis Report
This completely updated and expanded report volume utilises the Datafile content to produce more than 200 clear tables, charts, graphs and maps to provide "at a glance" insights into high-level trends and significant developments. Areas covered include:
Product managers at pharma/biotech companies with original biologics: Identify how many biosimilars versions of your products are being developed and by whom Product managers at biosimilar developers: Know how many biosimilars are being developed in different therapy areas or of different originator products so that you can identify opportunity gaps/areas with less competition Heads of licensing at pharma/biotech companies: Use the database to identify biosimilars developers that may want to license in/out their products - whilst also assessing the competitive environment for any products that they may currently license. Investment managers at venture capital firms, seed funding bodies and investment banks: Assess the investment potential of companies and their development pipelines: the risks are high but potential reward is great for those that bring product to market.